Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

William Ford Biography and Net Worth

Director of Royalty Pharma

Bill Ford is the CEO of General Atlantic, a leading global growth equity firm. Mr. Ford joined General Atlantic in 1991 and became CEO in 2007. Under Mr. Ford’s leadership, General Atlantic has expanded its global presence, increased its capital base, and deepened its capabilities to identify and partner with high-potential growth companies across multiple business sectors and geographies. Mr. Ford currently serves on the boards of BlackRock, ByteDance and IHS Markit and previously served on the boards of Axel Springer, e*Trade, First Republic Bank, Priceline, and Tory Burch, among others. Mr. Ford is involved with several educational and not-for-profit organizations. He serves as Chair of The Rockefeller University and sits on the boards of EMPEA (Emerging Markets Private Equity Association), Endeavor, and Memorial Sloan Kettering Cancer Center. From 2001 to 2013, he served as a Trustee of Amherst College and currently serves on the Investment Committee for the College’s endowment. Prior to joining General Atlantic, Mr. Ford was an investment banker at Morgan Stanley & Company. Mr. Ford received his BA from Amherst College and his MBA from Stanford Graduate School of Business.

What is William E. Ford's net worth?: The estimated net worth of William E. Ford is at least $338,631.30 as of April 14th, 2022. Mr. Ford owns 12,915 shares of Royalty Pharma stock worth more than $338,631 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Ford may own. Learn More about William E. Ford's net worth.
How do I contact William E. Ford?: The corporate mailing address for Mr. Ford and other Royalty Pharma executives is 110 E 59th Street, New York NY, 10022. Royalty Pharma can also be reached via phone at 212-883-0200 and via email at [email protected]. Learn More on William E. Ford's contact information.
Has William E. Ford been buying or selling shares of Royalty Pharma?: William E. Ford has not been actively trading shares of Royalty Pharma over the course of the past ninety days. Most recently, on Thursday, June 18th, William E. Ford bought 1,500,000 shares of Royalty Pharma stock. The stock was acquired at an average cost of $28.00 per share, with a total value of $42,000,000.00. Learn More on William E. Ford's trading history.
Who are Royalty Pharma's active insiders?: Royalty Pharma's insider roster includes Terrance Coyne (CFO), Henry Fernandez (Director), William Ford (Director), Mario Giuliani (Director), Pablo Legorreta (Founder & Chief Executive Officer and Chairman), George Lloyd (EVP), James Reddoch (EVP), Rory Riggs (Director), Sanjay Singh (CRO), and Marshall Urist (EVP). Learn More on Royalty Pharma's active insiders.
Are insiders buying or selling shares of Royalty Pharma?: In the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 312,631 shares worth more than $8,860,323.39. The most recent insider tranaction occured on January, 4th when Director Rory B Riggs sold 35,702 shares worth more than $983,590.10. Insiders at Royalty Pharma own 18.9% of the company. Learn More about insider trades at Royalty Pharma.
Information on this page was last updated on 1/4/2024.

William E. Ford Insider Trading History at Royalty Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/18/2020	Buy	1,500,000	$28.00	$42,000,000.00

William E. Ford Buying and Selling Activity at Royalty Pharma

Royalty Pharma Company Overview

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Today's Range

Now: $26.42

$26.23

$26.42

50 Day Range

MA: $27.35

$25.58

$28.38

2 Week Range

Now: $26.42

$25.10

$31.66

Volume

606,455 shs

Average Volume

2,618,051 shs

Market Capitalization

$15.57 billion

P/E Ratio

13.69

Dividend Yield

3.23%

Beta

0.47

Trump won. Buy this coin now.

From Weiss Ratings | Ad